The incidence of cutaneous malignant melanoma (CMM) is significantly increasing worldwide.[...].

BIOCEV 1st Faculty of Medicine Charles University 252 50 Vestec Czech Republic

Department of Dermatovenereology 1st Faculty of Medicine Charles University and General University Hospital 128 08 Prague Czech Republic

Institute of Anatomy 1st Faculty of Medicine Charles University 128 00 Prague Czech Republic

Zobrazit více v PubMed

Brustugun O.T., Møller B., Helland Å. Years of life lost as a measure of cancer burden on a national level. Br. J. Cancer. 2020;111:1014–1020. doi: 10.1038/bjc.2014.364. PubMed DOI PMC

Krayem M., Aftimos P., Najem A., van den Hooven T., van den Berg A., Hovestad-Bijl L., de Wijn R., Hilhorst R., Ruijtenbeek R., Sabbah M., et al. Kinome profiling to predict sensitivity to MAPK inhibition in melanoma and to provide new insights into intrinsic and acquired mechanism of resistance. Cancers. 2020;12:512. doi: 10.3390/cancers12020512. PubMed DOI PMC

Palušová V., Renzová T., Verlande A., Vaclová T., Medková M., Cetlová L., Sedláčková M., Hříbková H., Slaninová I., Krutá M., et al. Dual targeting of BRAF and mTOR signaling in melanoma cells with pyridinyl imidazole compounds. Cancers. 2020;12:1516. PubMed PMC

Ruggiero C.F., Malpicci D., Fattore L., Madonna G., Vanella V., Mallardo D., Liguoro D., Salvati V., Capone M., Bedogni B., et al. ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin. Cancers. 2019;11:1425. doi: 10.3390/cancers11101425. PubMed DOI PMC

Penas C., Apraiz A., Muñoa I., Arroyo-Berdugo Y., Rasero J., Ezkurra P.A., Velasco V., Subiran N., Bosserhoff A.K., Alonso S., et al. RKIP regulates differentiation-related features in melanocytic cells. Cancers. 2020;12:1451. doi: 10.3390/cancers12061451. PubMed DOI PMC

Tétu P., Delyon J., André J., Reger de Moura C., Sabbah M., Ghanem G.E., Battistella M., Mourah S., Lebbé C., Dumaz. N. FGF2 Induces resistance to Nilotinib through MAPK pathway activation in KIT mutated melanoma. Cancers. 2020;12:1062. PubMed PMC

Kodet O., Kučera J., Strnadová K., Dvořánková B., Štork J., Lacina L., Smetana K., Jr. Cutaneous melanoma dissemination is dependent on the malignant cell properties and factors of intercellular crosstalk in the cancer microenvironment (Review) Int. J. Oncol. 2020;57:619–630. doi: 10.3892/ijo.2020.5090. PubMed DOI PMC

Diazzi S., Tartare-Deckert S., Deckert M. Bad neighborhood: Fibrotic stroma as a new player in melanoma resistance to targeted therapies. Cancers. 2020;12:1364. doi: 10.3390/cancers12061364. PubMed DOI PMC

Balakirouchenane D., Guégan S., Csajka C., Jouinot A., Heidelberger V., Puszkiel A., Zehou Khoudour N., Courlet P., Kramkimel N., Lheure C., et al. Population pharmacokinetics/pharmacodynamics of Dabrafenib plus Trametinib in patients with BRAF-mutated metastatic melanoma. Cancers. 2020;12:931. doi: 10.3390/cancers12040931. PubMed DOI PMC

Del Bianco P., Stagni C., Giunco S., Fabozzi A., Elefanti L., Pellegrini S., Vecchiato A., Pigozzo J., Zamuner C., De Rossi A., et al. TERT promoter mutations differently correlate with the clinical outcome of MAPK inhibitor-treated melanoma patients. Cancers. 2020;12:946. doi: 10.3390/cancers12040946. PubMed DOI PMC

Huynh S., Mortier L., Dutriaux C., Maubec E., Boileau M., Dereure O., Leccia M.-T., Arnault J.-P., Brunet-Possenti F., Aubin F., et al. Combined therapy with anti-PD1 and BRAF and/or MEK inhibitor for advanced melanoma: A multicenter cohort study. Cancers. 2020;12:1666. doi: 10.3390/cancers12061666. PubMed DOI PMC

Lebbé C., Dutriaux C., Lesimple T., Kruit W., Kerger J., Thomas L., Guillot B., de Braud F., Garbe C., Grob J.J., et al. Pimasertib versus Dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: Phase II, randomised, controlled trial with crossover. Cancers. 2020;12:1727. PubMed PMC

Greco A., Safi D., Swami U., Ginader T., Milhem M., Zakharia Y. Efficacy and adverse events in metastatic melanoma patients treated with combination BRAF plus MEK inhibitors versus BRAF inhibitors: A systematic review. Cancers. 2019;11:1950. doi: 10.3390/cancers11121950. PubMed DOI PMC

Becco P., Gallo G., Poletto S., Pio Manlio Frascione M., Crotto L., Zaccagna A., Paruzzo L., Caravelli D., Carnevale-Schianca F., Aglietta M. Melanoma brain Metastases in the era of target therapies: An overview. Cancers. 2020;12:1640. doi: 10.3390/cancers12061640. PubMed DOI PMC

Hellmund P., Schmitt J., Roessler M., Meier F., Schoffer O. Targeted and checkpoint inhibitor therapy of metastatic malignant melanoma in germany, 2000–2016. Cancers. 2020;12:2354. doi: 10.3390/cancers12092354. PubMed DOI PMC

Autoimmunity, cancer and COVID-19 abnormally activate wound healing pathways: critical role of inflammation

Exosomes produced by melanoma cells significantly influence the biological properties of normal and cancer-associated fibroblasts